Tvardi Therapeutics, Inc. (TVRD) - Total Liabilities
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has total liabilities worth $11.31 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tvardi Therapeutics, Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Tvardi Therapeutics, Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Tvardi Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TVRD total asset value.
Tvardi Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eureka Design Public Company Limited
BK:UREKA
|
Thailand | ฿324.34 Million |
|
Estrella Immunopharma Inc.
NASDAQ:ESLA
|
USA | $9.26 Million |
|
Pili International Multimedia Co Ltd
TWO:8450
|
Taiwan | NT$559.52 Million |
|
Mistral Iberia Real Estate SOCIMI S.A.
MC:YMIB
|
Spain | €11.51 Million |
|
Fold Holdings, Inc. Class A Common Stock
NASDAQ:FLD
|
USA | $41.98 Million |
|
Gryphon Digital Mining Inc.
NASDAQ:GRYP
|
USA | $17.19 Million |
|
Is Girisim Sermayesi Yatirim Ortakligi AS
IS:ISGSY
|
Turkey | TL4.03 Million |
|
CESSATECH A/S DK -20
F:8GN
|
Germany | €1.38 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Tvardi Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Tvardi Therapeutics, Inc. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tvardi Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual total liabilities of Tvardi Therapeutics, Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.13 Million | -77.02% |
| 2024-12-31 | $48.42 Million | -45.63% |
| 2023-12-31 | $89.06 Million | -1.21% |
| 2022-12-31 | $90.15 Million | +361.49% |
| 2021-12-31 | $19.53 Million | -11.83% |
| 2020-12-31 | $22.16 Million | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more